NASDAQ:CRMD CorMedix (CRMD) Stock Price, News & Analysis $7.85 -0.25 (-3.09%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$7.85 0.00 (0.00%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About CorMedix Stock (NASDAQ:CRMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CorMedix alerts:Sign Up Key Stats Today's Range$7.79▼$8.1150-Day Range$7.19▼$8.6152-Week Range$6.13▼$13.02Volume894,232 shsAverage Volume1.07 million shsMarket Capitalization$611.83 millionP/E Ratio4.13Dividend YieldN/APrice Target$15.00Consensus RatingModerate Buy Company Overview CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing products designed to prevent and treat life-threatening infections and inflammatory conditions. The company’s lead product is DefenCath, a catheter-lock solution containing taurolidine and citrate. DefenCath is approved by the U.S. Food and Drug Administration for use in adult patients with kidney failure who are receiving chronic hemodialysis through a central venous catheter. It is intended to reduce the risk of catheter-related bloodstream infections, a significant complication for patients who depend on long-term vascular access. CorMedix markets DefenCath in the United States through its commercial operations and continues to evaluate potential additional applications for its technology. CorMedix was founded in 2006 and is headquartered in Berkeley Heights, New Jersey. The company is led by Khoso Bal, who serves as president and chief executive officer. Its business is primarily centered on the development and commercialization of anti-infective products for use in healthcare settings.AI Generated. May Contain Errors. Read More CorMedix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreCRMD MarketRank™: 3.225073509755 of 5 starsCorMedix scored higher than 65% of companies evaluated by MarketBeat, and ranked 279th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingCorMedix has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialCorMedix has a consensus price target of $15.00, representing about 91.1% upside from its current price of $7.85.Amount of Analyst CoverageCorMedix has only been the subject of 4 research reports in the past 90 days.Read more about CorMedix's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-74.07% Earnings GrowthEarnings for CorMedix are expected to decrease by -74.07% in the coming year, from $0.54 to $0.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CorMedix is 4.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.82.Price to Earnings Ratio vs. SectorThe P/E ratio of CorMedix is 4.13, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.89.Price to Earnings Growth RatioCorMedix has a PEG Ratio of 1.45. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCorMedix has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CorMedix's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.50% of the float of CorMedix has been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 18.9, which indicates bearish sentiment.Change versus previous monthShort interest in CorMedix has recently decreased by 4.81%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.67 News SentimentCorMedix has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for CorMedix this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for CRMD on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat Follows3 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have not sold or bought any company stock.Percentage Held by Insiders3.50% of the stock of CorMedix is held by insiders.Percentage Held by Institutions34.18% of the stock of CorMedix is held by institutions.Read more about CorMedix's insider trading history. Receive CRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRMD Stock News HeadlinesCorMedix (NASDAQ:CRMD) Earns Buy Rating from Needham & Company LLCOctober 21 at 1:18 AM | americanbankingnews.comCorMedix Therapeutics Announces FDA Acceptance For Priority Review Of Supplemental NDA For REZZAYO® For Prophylaxis Of Invasive Fungal DiseasesOctober 19, 2026 | marketscreener.comMTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely. Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years.October 24 at 1:00 AM | Porter & Company (Ad)CorMedix Receives FDA Priority Review for Rezzayo Fungal Disease PreventionOctober 19, 2026 | finance.yahoo.comCorMedix Gains FDA Priority Review For REZZAYO's Potential New IndicationOctober 19, 2026 | rttnews.comCorMedix Therapeutics Announces FDA Acceptance and Priority Review of REZZAYO sNDA for Prophylaxis of Invasive Fungal DiseaseOctober 19, 2026 | quiverquant.comQCormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal DiseasesOctober 19, 2026 | globenewswire.comActinium Pharmaceuticals Names Matt David CFOOctober 15, 2026 | rttnews.comSee More Headlines CRMD Stock Analysis - Frequently Asked Questions How have CRMD shares performed this year? CorMedix's stock was trading at $11.63 at the beginning of the year. Since then, CRMD shares have decreased by 32.5% and is now trading at $7.85. How were CorMedix's earnings last quarter? CorMedix Inc (NASDAQ:CRMD) released its earnings results on Thursday, August, 13th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.24 by $0.05. The business had revenue of $101.93 million for the quarter, compared to analyst estimates of $96.04 million. CorMedix had a net margin of 40.49% and a trailing twelve-month return on equity of 40.52%. Read the conference call transcript. When did CorMedix's stock split? CorMedix shares reverse split on the morning of Tuesday, March 26th 2019.The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Is CorMedix doing a stock buyback? CorMedix's Board of Directors approved a stock buyback plan on Monday, February 2nd 2026, which permits the company to repurchase $75,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 12.3% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's management believes its shares are undervalued. Who are CorMedix's major shareholders? CorMedix's top institutional shareholders include State of Alaska Department of Revenue (0.07%) and Sigma Planning Corp (0.04%). Insiders that own company stock include Joseph Todisco, Myron Kaplan, Kaufman Beth Zelnick, Elizabeth Hurlburt, Steven W Lefkowitz, Erin Mistry and Alan W Dunton. View institutional ownership trends. How do I buy shares of CorMedix? Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA), Alibaba Group (BABA), Broadcom (AVGO) and Palantir Technologies (PLTR). Company Calendar Last Earnings8/13/2026Today10/24/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CRMD's financial health is in the Red zone, according to TradeSmith. CRMD has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CRMD CIK1410098 Webwww.cormedix.com Phone(908) 517-9500Fax908-429-4307Employees191Year Founded2006Price Target and Rating Average Price Target for CorMedix$15.00 High Price Target$19.00 Low Price Target$13.00 Potential Upside/Downside+91.1%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$2.14 Trailing P/E Ratio4.13 Forward P/E Ratio14.54 P/E Growth1.45Net Income$163.05 million Net Margins40.49% Pretax Margin44.00% Return on Equity40.52% Return on Assets20.61% Debt Debt-to-Equity Ratio0.31 Current Ratio2.56 Quick Ratio2.36 Sales & Book Value Annual Sales$311.71 million Price / Sales1.96 Cash Flow$2.04 per share Price / Cash Flow3.84 Book Value$5.14 per share Price / Book1.53Miscellaneous Outstanding Shares77,940,000Free Float75,216,000Market Cap$611.83 million OptionableOptionable Beta1.40 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:CRMD) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFederal Reserve’s Disturbing Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredMissed this in 2024? Here’s your second chanceIn April 2024, gold had gone nowhere for 13 years - then it surged to a record high, more than doubling in val...Traders Agency | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe data center backlash is creating a rare investing opportunityA new Gallup poll shows 70% of Americans want AI data centers kept out of their communities - and futurist Geo...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
